North Carolina
How Association for Molecular Pathology v. Myriad Genetics, Inc. applies in North Carolina: state-specific rules, key cases, and bar exam notes for Intellectual Property (Patent Law).
North Carolina courts align with the federal standard established in 'Association for Molecular Pathology v. Myriad Genetics, Inc.' concerning the patent-eligibility of natural phenomena and products of nature. The state emphasizes the importance of distinguishing between patentable and non-patentable inventions in biotechnology.
In North Carolina, similar to the federal rule, naturally occurring genes and their correlations are not patentable unless they have been significantly altered or have new utility through human intervention.
The North Carolina Court of Appeals held that isolated DNA sequences are not patentable unless they exhibit new and non-obvious characteristics.
The court reaffirmed that the utility and innovation of biogenetic compositions must be proven for patent eligibility.
This case noted the necessity of a clear distinction between nature and human-made enhancements for patent examination.
North Carolina's approach mirrors the federal standard set forth by the U.S. Supreme Court in Myriad, especially in recognizing that merely isolating genetic material does not make it patentable. However, North Carolina courts emphasize the need for substantial human intervention in their analyses.
Questions related to the patent eligibility of biotechnological inventions often arise in the North Carolina bar exam, making knowledge of the Myriad case particularly relevant.